Jazz Pharmaceuticals PLC
NASDAQ:JAZZ

Watchlist Manager
Jazz Pharmaceuticals PLC Logo
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Watchlist
Price: 167.51 USD 1.54% Market Closed
Market Cap: 10.2B USD

Operating Margin
Jazz Pharmaceuticals PLC

10.9%
Current
12%
Average
6.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
10.9%
=
Operating Profit
453.9m
/
Revenue
4.2B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IE
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
10.2B USD
11%
US
Eli Lilly and Co
NYSE:LLY
966.2B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
506.7B USD
27%
CH
Roche Holding AG
SIX:ROG
252.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP
24%
CH
Novartis AG
SIX:NOVN
203.1B CHF
33%
US
Merck & Co Inc
NYSE:MRK
245.9B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
11%
US
Pfizer Inc
NYSE:PFE
147.4B USD
29%
No Stocks Found

Jazz Pharmaceuticals PLC
Glance View

In the bustling world of global pharmaceuticals, Jazz Pharmaceuticals PLC has carved out a niche for itself through its focus on specialty pharmaceuticals addressing unmet medical needs. Founded in 2003, Jazz has grown significantly by acquiring and developing unique products that serve smaller patient populations but address significant health challenges. Its journey is one of careful strategy and thoughtful innovation. The company first gained attention with its sleep disorder portfolio, most notably Xyrem, a treatment for narcolepsy that quickly became a cornerstone of its revenue stream. Jazz's adeptness at navigating complex regulatory and market environments has played a crucial role in its success, allowing it to maintain a stronghold in niche therapeutic markets. Building on its initial successes, Jazz began to diversify its portfolio, expanding into oncology and neuroscience. The acquisition of companies like Celator Pharmaceuticals and GW Pharmaceuticals was a strategic move to broaden its research capabilities and tap into the lucrative, yet challenging, segments of cancer and cannabinoid therapies. Jazz’s pipeline is rich with promising candidates, reflecting its commitment to long-term growth through innovation. Central to its business model is the commercialization of these specialized, high-value drugs, which are marketed to healthcare providers and directly impact patient outcomes. By focusing on diseases with few effective treatments, Jazz positions itself as a leader in transforming lives, all while sustaining its financial health through carefully managed margins and a global reach in its distribution and research efforts.

JAZZ Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
10.9%
=
Operating Profit
453.9m
/
Revenue
4.2B
What is the Operating Margin of Jazz Pharmaceuticals PLC?

Based on Jazz Pharmaceuticals PLC's most recent financial statements, the company has Operating Margin of 10.9%.

Back to Top